2024
Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma
Caruso C, Canonica G, Patel M, Smith A, Liu M, Alfonso-Cristancho R, Price R, Jakes R, Demetriou L, Valero A, Köhler T, Pilette C, Chupp G, Brusselle G, Howarth P. Prospective REALITI-A study: 2-year real-world benefits of mepolizumab in severe asthma. CHEST Pulmonary 2024, 100107. DOI: 10.1016/j.chpulm.2024.100107.Peer-Reviewed Original ResearchFollow-up periodMepolizumab treatmentAdverse eventsSevere asthmaRate of clinically significant asthma exacerbationsFollow-upMonoclonal antibodies targeting interleukin-5Clinically significant asthma exacerbationsMaintenance oral corticosteroidsAssociated with sustained reductionsProportion of patientsACQ-5 scoresAsthma Control QuestionnaireForced expiratory volumeOral corticosteroidsWell-toleratedACQ-5Clinical benefitMepolizumabProspective studyWeeks 0Asthma exacerbationsInterleukin-5Expiratory volumeSustained reduction
2019
Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 4 Year Follow-Up Results from a Large Scale Prospective Study
Chupp G, Kline J, Khatri S, McEvoy C, Silvestri G, Shifren A, Castro M, Bansal S, McClelland M, Dransfield M, Olivenstein R, Kahlstrom R, Ryan S, Lawson E, Simoff M, Wahidi M, Lamb C, Ferguson J, Haas A, Hogarth D, Tejedor R, Toth J, Majid A, Fitzgerald J, Enfield K, Grubb G, Laviolette M. Long-Term Efficacy and Safety of Bronchial Thermoplasty (BT): 4 Year Follow-Up Results from a Large Scale Prospective Study. 2019, a2683-a2683. DOI: 10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a2683.Peer-Reviewed Original Research